Latest VTRS news

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga · Wed, 23 Sep 2026 07:05:06 -0400

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

PRNewsWire · Wed, 16 Sep 2026 06:59:00 -0400

Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy).

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

Seeking Alpha · Wed, 09 Sep 2026 14:47:05 -0400

Viatris' Q2 showed better earnings quality, with adjusted net income and EPS up 11% while free cash flow doubled year-over-year. Deleveraging remains on track, while buybacks and dividends demonstrate that stronger cash generation is already supporting shareholder returns. Pipeline progress and new-product approvals provide additional growth optionality beyond the mature portfolio, with key Phase 3 assets approaching important milestones.

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · Wed, 09 Sep 2026 10:40:50 -0400

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

17 Ideal 'Safer' Buyable August Dogs Dug Up After 10 Years

Seeking Alpha · Fri, 28 Aug 2026 11:17:28 -0400

I analyze 89 top Ten-Year Collected Dividend Dogs, focusing on yield-based strategies and safety via free cash flow coverage. Ten-year top dividend dogs project average net gains of 39.61% by August 2027, with risk profiles generally below market volatility. Seventeen 'safer' dogs meet the ideal of annual dividends from $1K invested exceeding share price, signaling strong income potential.

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

Zacks Investment Research · Thu, 27 Aug 2026 14:11:04 -0400

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

Here's Why Viatris (VTRS) is a Strong Value Stock

Zacks Investment Research · Tue, 18 Aug 2026 10:41:26 -0400

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Market information is provided for research and visualization and is not investment advice.